Literature DB >> 25014035

Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.

Hiroshi Mabuchi1, Atsushi Nohara2, Tohru Noguchi2, Junji Kobayashi2, Masa-aki Kawashiri3, Takeshi Inoue3, Mika Mori3, Hayato Tada3, Chiaki Nakanishi3, Kunimasa Yagi3, Masakazu Yamagishi3, Kousei Ueda4, Tadayoshi Takegoshi5, Susumu Miyamoto6, Akihiro Inazu7, Junji Koizumi8.   

Abstract

BACKGROUNDS: Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by hypercholesterolemia, tendon xanthomas, and premature coronary heart disease. FH is caused by mutations of "FH genes," which include the LDL-receptor (LDLR), apolipoprotein B-100 (APOB) or proprotein convertase subtilisin/kexin type 9 (PCSK9). We evaluated the usefulness of FH gene analysis for diagnosing homozygous FH (homo-FH), particularly in cases caused by gain-of-function (g-o-f) mutations in PCSK9 (PCSK9 E32K).
OBJECTIVES: To evaluate the frequency of homo-FH caused by PCSK9 E32K compared with FH due to other genetic causes and to report the phenotypic features of homo-FH caused by PCSK9 E32K.
METHODS: Genomic DNA was prepared from white blood cells, and LDLR and PCSK9 mutations were identified using the Invader assay method.
RESULTS: Of the 1055 hetero-FH patients, 62 patients (5.9%) carried the PCSK9 E32K mutation, while in the 82 alleles of 41 homo-FH patients, 13 (15.9%) had double mutations of LDLR allele and PCSK9 E32K mutation. Mean plasma total cholesterol (TC) (9.93 ± 2.95 mmol/L, mean ± SD) in true homo-FH cases with PCSK9 E32K or double hetero-FH cases with PCSK9 E32K and LDLR mutations were significantly lower than those in true homo-FH (18.06 ± 4.96 mmol/L) and compound heterozygous cases with LDLR mutations (14.84 ± 1.62 mmol/L). Mean plasma TC concentrations in the 59 hetero-FH cases with PCSK9 E32K (7.21 ± 1.55 mmol/L) were significantly lower than those (8.94 ± 1.53 mmol/L) in the hetero-FH by LDLR mutations.
CONCLUSIONS: FH caused by PCSK9 g-o-f mutations is relatively common in Japan and causes a mild type of homo- and hetero-FH compared with FH caused by LDLR mutations.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Heterozygous-FH (Hetero-FH); Homozygous familial hypercholesterolemia (Homo-FH); LDL-receptor; PCSK9

Mesh:

Substances:

Year:  2014        PMID: 25014035     DOI: 10.1016/j.atherosclerosis.2014.06.005

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  25 in total

1.  Infantile Cases of Sitosterolaemia with Novel Mutations in the ABCG5 Gene: Extreme Hypercholesterolaemia is Exacerbated by Breastfeeding.

Authors:  Hayato Tada; Masa-Aki Kawashiri; Mutsuko Takata; Kunihiro Matsunami; Atsushi Imamura; Misayo Matsuyama; Hirotake Sawada; Hiroyuki Nunoi; Tetsuo Konno; Kenshi Hayashi; Atsushi Nohara; Akihiro Inazu; Junji Kobayashi; Hiroshi Mabuchi; Masakazu Yamagishi
Journal:  JIMD Rep       Date:  2015-02-10

2.  Therapy: PCSK9 inhibitors for treating familial hypercholesterolaemia.

Authors:  Hiroshi Mabuchi; Atsushi Nohara
Journal:  Nat Rev Endocrinol       Date:  2014-11-18       Impact factor: 43.330

3.  Novel compound heterozygous mutations in low density lipoprotein receptor gene causes a severe phenotype in a Chinese hypercholesterolemia family.

Authors:  Xinyao Cheng; Yifang Huang; Xueping Qiu; Xiaohuan Cheng; Yalei Jin; Yafei Hu; Bing Yang; Jingbo Zhao; Yuhua Lei; Fang Zheng
Journal:  Exp Ther Med       Date:  2018-05-23       Impact factor: 2.447

Review 4.  Genetics of familial hypercholesterolemia.

Authors:  Ariel Brautbar; Emili Leary; Kristen Rasmussen; Don P Wilson; Robert D Steiner; Salim Virani
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

5.  Polygenic risk scores for low-density lipoprotein cholesterol and familial hypercholesterolemia.

Authors:  Akihiro Nomura; Takehiro Sato; Hayato Tada; Takayuki Kannon; Kazuyoshi Hosomichi; Hiromasa Tsujiguchi; Hiroyuki Nakamura; Masayuki Takamura; Atsushi Tajima; Masa-Aki Kawashiri
Journal:  J Hum Genet       Date:  2021-05-10       Impact factor: 3.172

6.  Genetic Analysis of Japanese Children Clinically Diagnosed with Familial Hypercholesterolemia.

Authors:  Keiko Nagahara; Tsuyoshi Nishibukuro; Yasuko Ogiwara; Kento Ikegawa; Hayato Tada; Masakazu Yamagishi; Masa-Aki Kawashiri; Ayako Ochi; Junya Toyoda; Yuya Nakano; Masanori Adachi; Katsumi Mizuno; Yukihiro Hasegawa; Kazushige Dobashi
Journal:  J Atheroscler Thromb       Date:  2021-05-20       Impact factor: 4.394

7.  Genetic testing of Korean familial hypercholesterolemia using whole-exome sequencing.

Authors:  Soo Min Han; Byungjin Hwang; Tae-gun Park; Do-Il Kim; Moo-Yong Rhee; Byoung-Kwon Lee; Young Keun Ahn; Byung Ryul Cho; Jeongtaek Woo; Seung-Ho Hur; Jin-Ok Jeong; Sungha Park; Yangsoo Jang; Min Goo Lee; Duhee Bang; Ji Hyun Lee; Sang-Hak Lee
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

Review 8.  Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).

Authors:  Rainer Schulz; Klaus-Dieter Schlüter; Ulrich Laufs
Journal:  Basic Res Cardiol       Date:  2015-01-20       Impact factor: 17.165

9.  PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia.

Authors:  Esra Kaya; Meral Kayıkçıoğlu; Aslı Tetik Vardarlı; Zuhal Eroğlu; Serdar Payzın; Levent Can
Journal:  Anatol J Cardiol       Date:  2017-08-02       Impact factor: 1.596

Review 10.  Familial hypercholesterolemia in Southeast and East Asia.

Authors:  Candace L Jackson; Magdi Zordok; Iftikhar J Kullo
Journal:  Am J Prev Cardiol       Date:  2021-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.